I’ve had several patients with psoriasis improve when they began dialysis for their chronic renal failure. Any insight as to what possible mechanism is at work here? — Charles Nagel,  PA-C, MPH, Huntsville, Tex.


Earlier small-sample studies (70s-90s) reported improved psoriatic lesions upon dialysis (particularly peritoneal). Mechanisms include decreased immunoglobulin G (IgG) (see Sobh et al. Nephrol Dial Transplant. 1987;2[5]:351-358), postulated removal (from bloodstream) of growth-promoting substances, psoriasis-related factors, activated polymorphonuclear leukocytes, interference with neutrophil migration (see Kuruvila et al. Indian J Dermatol Venereol Leprol. 1998;64[3]:146-149), fibronectin level (see Vasil’eva et al. Lab Delo. 1991;3:27-28), other. 


Conversely, other studies implicate dialysis-induced growth factor, cytokines, and chemokines in psoriasis development (see Yamamoto et al. J Eur Acad Dermatol Venereol. 2006;20[9]:1139-1140). Severe psoriasis independently predicts chronic kidney disease (see Wan et al. BMJ. 2013;347:f5961). Studies focusing on factors shared by both conditions could be informative. 


Current psoriasis treatment includes topical and systemic therapies (corticosteroids, emollients, retinoids, phototherapy, immunosuppressants, biologic immune modifiers, other).– Houry Puzantian,PhD; assistant professor, College of Nursing, University of Illinois at Chicago; member, Council of Advanced Practitioners of the National Kidney Foundation (189-3)



These are letters from practitioners around the country who want to share their clinical problems and successes, observations and pearls with their colleagues. We invite you to participate. If you have a clinical pearl, submit it here.